Uncategorized

At almost 80,000 square feet, the addition will allow the Japan-based to create jobs for in-office and hybrid workers in the region.

Zynex, Inc. will hold a conference call on Thursday, July 27, 2023 at 4:15 PM Eastern Time to discuss its financial results for the second quarter, 2023 ended June 30, 2023.

Schrödinger, Inc. today reported that on July 14, 2023, the company granted (i) non-statutory stock options to purchase 10,250 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 6,225 shares of the company’s common stock to nine newly hired employees.

Rarecells is thrilled to announce its breakthrough publication, written in partnership with the team of Dr. Azra Raza from Columbia University Irving Medical Center, revealing for the first time the presence of circulating giant cancer cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS).

With Eisai and Biogen’s Leqembi now fully approved, researchers are exploring combinations—including with therapies targeting tau and microglial function—that could increase its effectiveness.

Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie’s disease), a non-interventional registry of up to 1,000 patients with Peyronie’s disease (PD).

Los volcanes han sido una fuerza poderosa de la naturaleza a lo largo de la historia de nuestro planeta. Estas maravillas geológicas pueden crear paisajes impresionantes y, al mismo tiempo, representar una amenaza significativa para las comunidades cercanas. Conozcamos algunos de los volcanes …

Karuna Therapeutics, Inc. announced that it will host a live conference call and webcast on Thursday, August 3, 2023 at 8:00 a.m. ET to review second quarter 2023 financial results and provide a general business update.

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to June 2023.

Biophytis SA announced that it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for Emergency Use Authorization in the United States for Sarconeos in the treatment of severe forms of COVID-19.